{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T11:04:46Z","timestamp":1788174286559,"version":"build-2803163510"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T00:00:00Z","timestamp":1697500800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2024,2]]},"DOI":"10.1007\/s10067-023-06793-4","type":"journal-article","created":{"date-parts":[[2023,10,17]],"date-time":"2023-10-17T02:01:22Z","timestamp":1697508082000},"page":"799-808","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Etanercept-associated episcleritis: a pediatric case report of a paradoxical adverse reaction and review of the literature"],"prefix":"10.1007","volume":"43","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4268-8603","authenticated-orcid":false,"given":"Batuhan","family":"K\u00fc\u00e7\u00fckali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4823-2076","authenticated-orcid":false,"given":"Deniz","family":"Gezgin Y\u0131ld\u0131r\u0131m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9493-9355","authenticated-orcid":false,"given":"Pelin","family":"Esmeray \u015eenol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5585-253X","authenticated-orcid":false,"given":"H\u00fcseyin Baran","family":"\u00d6zdemir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6530-9672","authenticated-orcid":false,"given":"Sevcan A.","family":"Bakkalo\u011flu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,17]]},"reference":[{"issue":"1","key":"6793_CR1","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1080\/09273948.2021.2023582","volume":"31","author":"M Tarsia","year":"2023","unstructured":"Tarsia M, Gaggiano C, Gessaroli E, Grosso S, Tosi GM, Frediani B et al (2023) Pediatric scleritis: an update. Ocul Immunol Inflamm 31(1):175\u2013184","journal-title":"Ocul Immunol Inflamm"},{"issue":"1527","key":"6793_CR2","first-page":"83","volume":"133","author":"P Samalia","year":"2020","unstructured":"Samalia P, Sims J, Niederer R (2020) Drug-induced ocular inflammation. N Z Med J 133(1527):83\u201394","journal-title":"N Z Med J"},{"issue":"4","key":"6793_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1016\/j.ajo.2013.05.026","volume":"156","author":"G Homayounfar","year":"2013","unstructured":"Homayounfar G, Nardone N, Borkar DS, Tham VM, Porco TC, Enanoria WT et al (2013) Incidence of scleritis and episcleritis: results from the Pacific Ocular Inflammation Study. Am J Ophthalmol 156(4):752\u2013758","journal-title":"Am J Ophthalmol"},{"issue":"4","key":"6793_CR4","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1080\/09273948.2017.1423333","volume":"27","author":"PD Majumder","year":"2019","unstructured":"Majumder PD, Ali S, George A, Ganesh S, Biswas J (2019) Clinical profile of scleritis in children. Ocul Immunol Inflamm 27(4):535\u2013539","journal-title":"Ocul Immunol Inflamm"},{"issue":"6","key":"6793_CR5","doi-asserted-by":"publisher","first-page":"664","DOI":"10.1111\/apt.15097","volume":"49","author":"UN Shivaji","year":"2019","unstructured":"Shivaji UN, Sharratt CL, Thomas T, Smith SCL, Iacucci M, Moran GW et al (2019) Review article: managing the adverse events caused by anti-TNF therapy in inflammatory bowel disease. Aliment Pharmacol Ther 49(6):664\u2013680","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"6793_CR6","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1586\/1744666X.2014.866038","volume":"10","author":"D Wendling","year":"2014","unstructured":"Wendling D, Prati C (2014) Paradoxical effects of anti-TNF-alpha agents in inflammatory diseases. Expert Rev Clin Immunol 10(1):159\u2013169","journal-title":"Expert Rev Clin Immunol"},{"key":"6793_CR7","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1159\/000479475","volume":"53","author":"L Puig","year":"2018","unstructured":"Puig L (2018) Paradoxical reactions: anti-tumor necrosis factor alpha agents, ustekinumab, secukinumab, ixekizumab, and others. Curr Probl Dermatol 53:49\u201363","journal-title":"Curr Probl Dermatol"},{"issue":"1","key":"6793_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/s12348-020-00202-6","volume":"10","author":"F Nicolela Susanna","year":"2020","unstructured":"Nicolela Susanna F, Pavesio C (2020) A review of ocular adverse events of biological anti-TNF drugs. J Ophthalmic Inflamm Infect 10(1):11","journal-title":"J Ophthalmic Inflamm Infect"},{"issue":"2","key":"6793_CR9","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1093\/rheumatology\/keaa595","volume":"60","author":"I Maccora","year":"2021","unstructured":"Maccora I, Fusco E, Marrani E, Ramanan AV, Simonini G (2021) Changing evidence over time: updated meta-analysis regarding anti-TNF efficacy in childhood chronic uveitis. Rheumatology 60(2):568\u2013587","journal-title":"Rheumatology"},{"issue":"11","key":"6793_CR10","doi-asserted-by":"publisher","first-page":"1529","DOI":"10.1002\/acr.22613","volume":"67","author":"I Foeldvari","year":"2015","unstructured":"Foeldvari I, Becker I, Horneff G (2015) Uveitis events during adalimumab, etanercept, and methotrexate therapy in juvenile idiopathic arthritis: data from the biologics in pediatric rheumatology registry. Arthritis Care Res (Hoboken) 67(11):1529\u20131535","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"8","key":"6793_CR11","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1093\/rheumatology\/keh658","volume":"44","author":"H Schmeling","year":"2005","unstructured":"Schmeling H, Horneff G (2005) Etanercept and uveitis in patients with juvenile idiopathic arthritis. Rheumatology (Oxford) 44(8):1008\u20131011","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"6793_CR12","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/art.20904","volume":"53","author":"JA Smith","year":"2005","unstructured":"Smith JA, Thompson DJ, Whitcup SM, Suhler E, Clarke G, Smith S et al (2005) A randomized, placebo-controlled, double-masked clinical trial of etanercept for the treatment of uveitis associated with juvenile idiopathic arthritis. Arthritis Rheum 53(1):18\u201323","journal-title":"Arthritis Rheum"},{"issue":"8","key":"6793_CR13","first-page":"1107","volume":"77","author":"T Constantin","year":"2018","unstructured":"Constantin T, Foeldvari I, Anton J, de Boer J, Czitrom-Guillaume S, Edelsten C et al (2018) Consensus-based recommendations for the management of uveitis associated with juvenile idiopathic arthritis: the SHARE initiative. Ann Rheum Dis 77(8):1107\u20131117","journal-title":"Ann Rheum Dis"},{"issue":"6","key":"6793_CR14","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1002\/acr.23871","volume":"71","author":"ST Angeles-Han","year":"2019","unstructured":"Angeles-Han ST, Ringold S, Beukelman T, Lovell D, Cuello CA, Becker ML et al (2019) 2019 American College of Rheumatology\/Arthritis Foundation guideline for the screening, monitoring, and treatment of juvenile idiopathic arthritis\u2013associated uveitis. Arthritis Care Res (Hoboken) 71(6):703\u2013716","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"6","key":"6793_CR15","doi-asserted-by":"publisher","first-page":"1391","DOI":"10.1093\/rheumatology\/kez449","volume":"59","author":"R Davies","year":"2020","unstructured":"Davies R, De Cock D, Kearsley-Fleet L, Southwood T, Baildam E, Beresford MW et al (2020) The risk of uveitis in patients with JIA receiving etanercept: the challenges of analysing real-world data. Rheumatology (Oxford) 59(6):1391\u20131397","journal-title":"Rheumatology (Oxford)"},{"issue":"8","key":"6793_CR16","doi-asserted-by":"publisher","first-page":"2447","DOI":"10.1002\/art.21197","volume":"52","author":"J Braun","year":"2005","unstructured":"Braun J, Baraliakos X, Listing J, Sieper J (2005) Decreased incidence of anterior uveitis in patients with ankylosing spondylitis treated with the anti-tumor necrosis factor agents infliximab and etanercept. Arthritis Rheum 52(8):2447\u20132451","journal-title":"Arthritis Rheum"},{"issue":"2","key":"6793_CR17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1007\/s40744-021-00296-x","volume":"8","author":"Y Li","year":"2021","unstructured":"Li Y, Mao X, Tang X, Mao H (2021) Efficacy and safety of anti-TNFalpha therapy for uveitis associated with juvenile idiopathic arthritis: a systematic review and meta-analysis. Rheumatol Ther 8(2):711\u2013727","journal-title":"Rheumatol Ther"},{"issue":"3","key":"6793_CR18","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1016\/j.semarthrit.2011.05.005","volume":"41","author":"D Wendling","year":"2011","unstructured":"Wendling D, Paccou J, Berthelot J-M, Flipo R-M, Guillaume-Czitrom S, Prati C et al (2011) New onset of uveitis during anti-tumor necrosis factor treatment for rheumatic diseases. Semin Arthritis Rheum 41(3):503\u2013510. https:\/\/doi.org\/10.1016\/j.semarthrit.2011.05.005","journal-title":"Semin Arthritis Rheum"},{"issue":"5","key":"6793_CR19","doi-asserted-by":"publisher","first-page":"1554","DOI":"10.1002\/art.23442","volume":"58","author":"PP Sfikakis","year":"2008","unstructured":"Sfikakis PP, Markomichelakis N (2008) Tumor necrosis factor inhibitors and uveitis: comment on the article by Lim et al. Arthritis Rheum 58(5):1554\u20131555","journal-title":"Arthritis Rheum"},{"issue":"3","key":"6793_CR20","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1002\/1529-0131(200106)45:3<252::AID-ART257>3.0.CO;2-5","volume":"45","author":"JR Smith","year":"2001","unstructured":"Smith JR, Levinson RD, Holland GN, Jabs DA, Robinson MR, Whitcup SM et al (2001) Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease. Arthritis Rheum 45(3):252\u2013257","journal-title":"Arthritis Rheum"},{"issue":"12","key":"6793_CR21","first-page":"2727","volume":"30","author":"AN Tiliakos","year":"2003","unstructured":"Tiliakos AN, Tiliakos NA (2003) Ocular inflammatory disease in patients with RA taking etanercept: is discontinuation of etanercept necessary? J Rheumatol 30(12):2727\u20132727","journal-title":"J Rheumatol"},{"issue":"9237","key":"6793_CR22","doi-asserted-by":"publisher","first-page":"1255","DOI":"10.1016\/S0140-6736(00)02799-9","volume":"356","author":"IR Edwards","year":"2000","unstructured":"Edwards IR, Aronson JK (2000) Adverse drug reactions: definitions, diagnosis, and management. Lancet 356(9237):1255\u20131259","journal-title":"Lancet"},{"issue":"2","key":"6793_CR23","doi-asserted-by":"publisher","first-page":"233","DOI":"10.3899\/jrheum.110865","volume":"39","author":"C Gaujoux-Viala","year":"2012","unstructured":"Gaujoux-Viala C, Giampietro C, Gaujoux T, Ea HK, Prati C, Orcel P et al (2012) Scleritis: a paradoxical effect of etanercept? Etanercept-associated inflammatory eye disease. J Rheumatol 39(2):233\u2013239","journal-title":"J Rheumatol"},{"issue":"2","key":"6793_CR24","doi-asserted-by":"publisher","first-page":"e161","DOI":"10.1111\/j.1755-3768.2010.02090.x","volume":"90","author":"Y Sassa","year":"2012","unstructured":"Sassa Y, Kawano Y, Yamana T, Mashima T, Ishibashi T (2012) A change in treatment from etanercept to infliximab was effective to control scleritis in a patient with rheumatoid arthritis. Acta Ophthalmol (Copenh) 90(2):e161\u2013e162","journal-title":"Acta Ophthalmol (Copenh)"},{"issue":"7","key":"6793_CR25","doi-asserted-by":"publisher","first-page":"511. e511-516","DOI":"10.1016\/j.jfo.2009.04.029","volume":"32","author":"J Le Garrec","year":"2009","unstructured":"Le Garrec J, Marcelli C, Mouriaux F (2009) Can tumor necrosis factor inhibitors induce sclero-uveitis? J Fr Ophtalmol 32(7):511. e511-516. https:\/\/doi.org\/10.1016\/j.jfo.2009.04.029","journal-title":"J Fr Ophtalmol"},{"issue":"7","key":"6793_CR26","doi-asserted-by":"publisher","first-page":"925","DOI":"10.1136\/bjo.87.7.925","volume":"87","author":"A Reddy","year":"2003","unstructured":"Reddy A, Backhouse O (2003) Does etanercept induce uveitis? Br J Ophthalmol 87(7):925\u2013925","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"6793_CR27","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1002\/art.22918","volume":"56","author":"LL Lim","year":"2007","unstructured":"Lim LL, Fraunfelder FW, Rosenbaum JT (2007) Do tumor necrosis factor inhibitors cause uveitis? A registry-based study. Arthritis Rheum 56(10):3248\u20133252","journal-title":"Arthritis Rheum"},{"issue":"5","key":"6793_CR28","doi-asserted-by":"publisher","first-page":"729","DOI":"10.1136\/ard.2007.077370","volume":"67","author":"LC Coates","year":"2008","unstructured":"Coates LC, McGonagle DG, Bennett AN, Emery P, Marzo-Ortega H (2008) Uveitis and tumour necrosis factor blockade in ankylosing spondylitis. Ann Rheum Dis 67(5):729\u2013730","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"6793_CR29","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1080\/09273940600659393","volume":"14","author":"M Taban","year":"2006","unstructured":"Taban M, Dupps WJ, Mandell B, Perez VL (2006) Etanercept (enbrel)-associated inflammatory eye disease: case report and review of the literature. Ocul Immunol Inflamm 14(3):145\u2013150","journal-title":"Ocul Immunol Inflamm"},{"issue":"3","key":"6793_CR30","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1016\/j.ophtha.2013.09.048","volume":"121","author":"G Levy-Clarke","year":"2014","unstructured":"Levy-Clarke G, Jabs DA, Read RW, Rosenbaum JT, Vitale A, Van Gelder RN (2014) Expert panel recommendations for the use of anti-tumor necrosis factor biologic agents in patients with ocular inflammatory disorders. Ophthalmology 121(3):785-796 e783","journal-title":"Ophthalmology"},{"issue":"5","key":"6793_CR31","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1007\/s00296-011-2126-1","volume":"32","author":"A Heiligenhaus","year":"2012","unstructured":"Heiligenhaus A, Michels H, Schumacher C, Kopp I, Neudorf U, Niehues T et al (2012) Evidence-based, interdisciplinary guidelines for anti-inflammatory treatment of uveitis associated with juvenile idiopathic arthritis. Rheumatol Int 32(5):1121\u20131133","journal-title":"Rheumatol Int"},{"issue":"4","key":"6793_CR32","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1056\/NEJM199901283400401","volume":"340","author":"ME Weinblatt","year":"1999","unstructured":"Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleischmann RM, Fox RI et al (1999) A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 340(4):253\u2013259","journal-title":"N Engl J Med"},{"issue":"5","key":"6793_CR33","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1517\/14712598.2014.896334","volume":"14","author":"H Marotte","year":"2014","unstructured":"Marotte H, Cimaz R (2014) Etanercept\u2013TNF receptor and IgG1 Fc fusion protein: is it different from other TNF blockers? Expert Opin Biol Ther 14(5):569\u2013572","journal-title":"Expert Opin Biol Ther"},{"issue":"8","key":"6793_CR34","doi-asserted-by":"publisher","first-page":"751","DOI":"10.3109\/02713683.2010.486520","volume":"35","author":"V Kakkassery","year":"2010","unstructured":"Kakkassery V, Mergler S, Pleyer U (2010) Anti-TNF-alpha treatment: a possible promoter in endogenous uveitis? observational report on six patients: occurrence of uveitis following etanercept treatment. Curr Eye Res 35(8):751\u2013756","journal-title":"Curr Eye Res"},{"issue":"Suppl 1","key":"6793_CR35","doi-asserted-by":"publisher","first-page":"I32","DOI":"10.1136\/ard.58.2008.i32","volume":"58","author":"G Kollias","year":"1999","unstructured":"Kollias G, Douni E, Kassiotis G, Kontoyiannis D (1999) The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease. Ann Rheum Dis 58(Suppl 1):I32-39. https:\/\/doi.org\/10.1136\/ard.58.2008.i32","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"6793_CR36","doi-asserted-by":"publisher","first-page":"3246","DOI":"10.1167\/iovs.06-1444","volume":"48","author":"S Sugita","year":"2007","unstructured":"Sugita S, Takase H, Taguchi C, Mochizuki M (2007) The role of soluble TNF receptors for TNF-alpha in uveitis. Invest Ophthalmol Vis Sci 48(7):3246\u20133252","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"4","key":"6793_CR37","first-page":"318","volume":"10","author":"S Berestizschevsky","year":"2008","unstructured":"Berestizschevsky S, Weinberger D, Avisar I, Avisar R (2008) Episcleritis associated with familial Mediterranean fever. Isr Med Assoc J 10(4):318\u2013319","journal-title":"Isr Med Assoc J"},{"issue":"2","key":"6793_CR38","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/0002-9394(85)90812-8","volume":"100","author":"J Scharf","year":"1985","unstructured":"Scharf J, Meyer E, Zonis S (1985) Episcleritis associated with familial Mediterranean fever. Am J Ophthalmol 100(2):337\u2013339","journal-title":"Am J Ophthalmol"},{"issue":"3","key":"6793_CR39","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1002\/acr.24483","volume":"74","author":"EJ Liebling","year":"2022","unstructured":"Liebling EJ, Faig W, Chang JC, Mendoza E, Moore N, Vicioso NL et al (2022) Temporal relationship between juvenile idiopathic arthritis disease activity and uveitis disease activity. Arthritis Care Res (Hoboken) 74(3):349\u2013354","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"6793_CR40","doi-asserted-by":"publisher","DOI":"10.1155\/2011\/696285","volume":"2011","author":"IP Chatziralli","year":"2011","unstructured":"Chatziralli IP, Kanonidou E, Chatzirallis A, Dimitriadis P, Keryttopoulos P (2011) Episcleritis related to drug-induced lupus erythematosus following infliximab therapy: a case report. Case Rep Med 2011:696285","journal-title":"Case Rep Med"},{"issue":"9","key":"6793_CR41","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1136\/bjophthalmol-2015-306902","volume":"100","author":"M Sainz-de-la-Maza","year":"2016","unstructured":"Sainz-de-la-Maza M, Molina N, Gonzalez-Gonzalez LA, Doctor PP, Tauber J, Foster CS (2016) Scleritis associated with relapsing polychondritis. Br J Ophthalmol 100(9):1290\u20131294","journal-title":"Br J Ophthalmol"},{"issue":"6","key":"6793_CR42","doi-asserted-by":"publisher","first-page":"1042","DOI":"10.1093\/rheumatology\/kem052","volume":"46","author":"C Botsios","year":"2007","unstructured":"Botsios C, Sfriso P, Ostuni PA, Todesco S, Punzi L (2007) Efficacy of the IL-1 receptor antagonist, anakinra, for the treatment of diffuse anterior scleritis in rheumatoid arthritis. Report of two cases. Rheumatology (Oxford) 46(6):1042\u20131043","journal-title":"Rheumatology (Oxford)"},{"issue":"12","key":"6793_CR43","doi-asserted-by":"publisher","first-page":"2317","DOI":"10.1016\/j.ophtha.2006.04.038","volume":"113","author":"A Galor","year":"2006","unstructured":"Galor A, Perez VL, Hammel JP, Lowder CY (2006) Differential effectiveness of etanercept and infliximab in the treatment of ocular inflammation. Ophthalmology 113(12):2317\u20132323","journal-title":"Ophthalmology"},{"issue":"2","key":"6793_CR44","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1001\/jamaophthalmol.2018.5413","volume":"137","author":"HMT Teo","year":"2019","unstructured":"Teo HMT, de Sa FF, Demirci H (2019) Association of blepharitis and ectropion with tumor necrosis factor alpha inhibitor treatment in Crohn disease. JAMA Ophthalmol 137(2):232\u2013233","journal-title":"JAMA Ophthalmol"},{"issue":"5","key":"6793_CR45","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1002\/acr.24963","volume":"75","author":"I Foeldvari","year":"2023","unstructured":"Foeldvari I, Maccora I, Petrushkin H, Rahman N, Anton J, de Boer J et al (2023) New and updated recommendations for the treatment of juvenile idiopathic arthritis-associated uveitis and idiopathic chronic anterior uveitis. Arthritis Care Res (Hoboken) 75(5):975\u2013982","journal-title":"Arthritis Care Res (Hoboken)"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-023-06793-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-023-06793-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,1]],"date-time":"2024-02-01T13:06:52Z","timestamp":1706792812000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-023-06793-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,17]]},"references-count":45,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,2]]}},"alternative-id":["6793"],"URL":"https:\/\/doi.org\/10.1007\/s10067-023-06793-4","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,17]]},"assertion":[{"value":"21 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 October 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The patient\u2019s and her family\u2019s consent has been obtained for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"None.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}